Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer

Laila Sara Arroyo Mühr, Andrea Gini, Emel Yilmaz, Sadaf S. Hassan, Camilla Lagheden, Emilie Hultin, Ainhoa Garcia Serrano, Agustin E. Ure, Helena Andersson, Roxana Merino, K. Miriam Elfström, Iacopo Baussano and Joakim Dillner ()
Additional contact information
Laila Sara Arroyo Mühr: F56
Andrea Gini: Prevention and Infections Branch
Emel Yilmaz: F56
Sadaf S. Hassan: F56
Camilla Lagheden: F56
Emilie Hultin: F56
Ainhoa Garcia Serrano: F56
Agustin E. Ure: F56
Helena Andersson: F56
Roxana Merino: F56
K. Miriam Elfström: F56
Iacopo Baussano: Prevention and Infections Branch
Joakim Dillner: F56

Nature Communications, 2024, vol. 15, issue 1, 1-8

Abstract: Abstract HPV vaccination with concomitant HPV-based screening of young women has been proposed for faster cervical cancer elimination. We describe the baseline results of a population-based trial of this strategy to reduce the incidence of HPV. All 89,547 women born 1994-1999 and resident in the capital region of Sweden were personally invited to concomitant HPV vaccination and HPV screening with 26,125 women (29.2%) enrolled between 2021-05-03 and 2022-12-31. Baseline HPV genotyping of cervical samples from the study participants finds, compared to pre-vaccination prevalences, a strong decline of HPV16 and 18 in birth cohorts previously offered vaccination, some decline for cross-protected HPV types but no decline for HPV types not targeted by vaccines. Our dynamic transmission modelling predicts that the trial could reduce the incidence of high-risk HPV infections among the 1994-1998 cohorts by 62-64% in 3 years. Baseline results are prevalences of HPV infection, validated transmission model projections, and power estimates for evaluating HPV incidence reductions at follow-up (+/−0.1% with 99.9% confidence). In conclusion, concomitant HPV vaccination and HPV screening appears to be a realistic option for faster cervical cancer elimination. Clinicaltrials.gov identifier: NCT04910802; EudraCT number: 2020-001169-34.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-47909-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47909-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-47909-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().